News for Modalis Therapeutics Corporation (4883.T)

Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).

Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)

Modalis Announces Partnership with Ginkgo Bioworks

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

MDL-101 preclinical data support efficacy and safety of a differentiated precision medicine approach for LAMA2 Congenital Muscular Dystrophy Preclinical data showing that our CRISPR-based... | April 19, 2023